ES2231667T3 - Inhibidores de la 3',5'-monofosfato de guanosina ciclico fosfodiesterasa. - Google Patents

Inhibidores de la 3',5'-monofosfato de guanosina ciclico fosfodiesterasa.

Info

Publication number
ES2231667T3
ES2231667T3 ES02701497T ES02701497T ES2231667T3 ES 2231667 T3 ES2231667 T3 ES 2231667T3 ES 02701497 T ES02701497 T ES 02701497T ES 02701497 T ES02701497 T ES 02701497T ES 2231667 T3 ES2231667 T3 ES 2231667T3
Authority
ES
Spain
Prior art keywords
alkyl
het
ethyl
optionally substituted
terminated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02701497T
Other languages
English (en)
Spanish (es)
Inventor
Stephen M. Pfizer Global R & D. Denton
Mark I. Pfizer Global R & D. Kemp
Sandra D. Pfizer Global R & D. Newman
David J. Pfizer Global R & D. Rawson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Application granted granted Critical
Publication of ES2231667T3 publication Critical patent/ES2231667T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES02701497T 2001-03-16 2002-03-04 Inhibidores de la 3',5'-monofosfato de guanosina ciclico fosfodiesterasa. Expired - Lifetime ES2231667T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0106661.2A GB0106661D0 (en) 2001-03-16 2001-03-16 Pharmaceutically active compounds
GB0106661 2001-03-16

Publications (1)

Publication Number Publication Date
ES2231667T3 true ES2231667T3 (es) 2005-05-16

Family

ID=9910932

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02701497T Expired - Lifetime ES2231667T3 (es) 2001-03-16 2002-03-04 Inhibidores de la 3',5'-monofosfato de guanosina ciclico fosfodiesterasa.

Country Status (10)

Country Link
EP (1) EP1368352B1 (https=)
JP (1) JP2004523585A (https=)
AT (1) ATE283856T1 (https=)
BR (1) BR0208154A (https=)
CA (1) CA2439528A1 (https=)
DE (1) DE60202134T2 (https=)
ES (1) ES2231667T3 (https=)
GB (1) GB0106661D0 (https=)
MX (1) MXPA03005937A (https=)
WO (1) WO2002074774A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE478872T1 (de) * 2002-03-28 2010-09-15 Ustav Ex Botan Av Cr V V I I O Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
WO2004054560A1 (en) 2002-12-13 2004-07-01 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
CN100374441C (zh) * 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
PL2256106T3 (pl) 2003-07-22 2015-08-31 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
WO2005028480A2 (en) * 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
US7485637B2 (en) 2005-01-04 2009-02-03 Hoffmann-La Roche Inc. Benzoyl-tetrahydropiperidine derivatives
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
DE602006010665D1 (en) 2005-02-07 2010-01-07 Hoffmann La Roche Heterocyclsche substituierte phenylmethanone als inhibitoren des glycintransporters 1
CA2598271A1 (en) * 2005-02-18 2006-08-24 Surface Logix, Inc. Pharmacokinetically improved compounds
US8017781B2 (en) 2005-11-15 2011-09-13 Vertex Pharmaceuticals Incorporated Azaindazoles useful as inhibitors of kinases
CA2629077C (en) * 2005-11-16 2014-03-18 F. Hoffmann-La Roche Ag Novel process for the preparation of thoc
US8071765B2 (en) * 2006-12-21 2011-12-06 Topharman Shanghai Co., Ltd. Process for the preparation of sildenafil and intermediates thereof
RU2470635C2 (ru) * 2007-05-11 2012-12-27 Сантен Фармасьютикал Ко., Лтд. Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза
JP5498392B2 (ja) 2007-11-30 2014-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
JP5453431B2 (ja) 2008-09-08 2014-03-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピラゾロピリミジン及びｃｎｓ障害の治療のためのそれらの使用
EP2379076B1 (en) 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
PE20120505A1 (es) 2009-03-31 2012-05-09 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
TWI393578B (zh) 2009-07-07 2013-04-21 Shl Group Ab 注射裝置
AP2012006631A0 (en) 2010-08-12 2012-12-31 Boehringer Ingelheim Int 6-Cycloalkyl-1, 5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A inhibitors
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
EP2699572B1 (en) 2011-04-21 2016-08-10 Origenis GmbH Heterocyclic compounds as kinase inhibitors
MX363696B (es) 2011-04-21 2019-03-28 Origenis Gmbh Pirazolo[4,3-d]pirimidinas utiles como inhibidores de cinasas.
KR20140138293A (ko) 2012-03-16 2014-12-03 액시킨 파마수티컬스 인코포레이티드 3,5-다이아미노피라졸 키나아제 억제제
WO2014060112A1 (en) 2012-10-19 2014-04-24 Origenis Gmbh Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
US10000482B2 (en) 2012-10-19 2018-06-19 Origenis Gmbh Kinase inhibitors
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
WO2015091428A1 (en) * 2013-12-20 2015-06-25 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
US9546163B2 (en) 2014-12-23 2017-01-17 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
PL3377495T3 (pl) 2015-11-16 2022-05-16 Topadur Pharma Ag Pochodne 2-fenylo-3,4-dihydropirolo[2,1-f] [1,2,4]triazynonu jako inhibitory fosfodiesterazy i ich zastosowania
CN105669680B (zh) * 2016-03-24 2018-02-23 南京药捷安康生物科技有限公司 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂
UY40234A (es) 2022-04-22 2023-11-15 Vertex Pharma Compuestos heteroarilo para el tratamiento del dolor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1493685A (en) * 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
US6225315B1 (en) * 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance
AP2002002455A0 (en) * 1999-10-11 2002-06-30 Pfizer 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.

Also Published As

Publication number Publication date
DE60202134T2 (de) 2005-11-24
ATE283856T1 (de) 2004-12-15
DE60202134D1 (en) 2005-01-05
GB0106661D0 (en) 2001-05-09
EP1368352A1 (en) 2003-12-10
CA2439528A1 (en) 2002-09-26
JP2004523585A (ja) 2004-08-05
BR0208154A (pt) 2004-03-02
MXPA03005937A (es) 2003-09-10
EP1368352B1 (en) 2004-12-01
WO2002074774A1 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
ES2231667T3 (es) Inhibidores de la 3',5'-monofosfato de guanosina ciclico fosfodiesterasa.
US6770645B2 (en) Pharmaceutically active compounds
ES2241994T3 (es) Compuestos pirazolo(4,3-d)pirimidinona como inhibidores de gmpc.
ES2232502T3 (es) Derivados de pirazolo(4,3-d)pirimidina.
ES2326119T3 (es) 5,7-diaminopirazolo(4,3-d)pirimidinas utiles en el tratamiento de la hipertension.
ES2351622T3 (es) 5,7-diaminopirazolo[4,3-d]pirimidinas con actividad inhibidora de la pde-5.
SK4562002A3 (en) 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)- dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors
MXPA00009938A (es) Compuestos farmaceuticamente activos.
US6784185B2 (en) Pharmaceutically active compounds
RS20080118A (sr) Piridinaminosulfonil supstituisani benzamidi kao inhibitori citohroma p450 3a4 (cyp3a4)
US6831074B2 (en) Pharmaceutically active compounds
EP1395589A1 (en) Imidazo-triazine derivatives as pde 5 inhibitors
US6794387B2 (en) Pharmaceutically active compounds
JP2002322180A (ja) 薬学的に活性な化合物
CA2585557C (en) Pyrazolo[4,3-d] pyrimidine derivatives useful as pde-5 inhibitors
EP1380293A1 (en) Bone metabolism improving agents
HK1078574B (en) Pyrazolo [4,3-d] pyrimidine derivatives
HK1069577B (en) Pyrazolo [4,3-d] pyrimidine derivatives